Masimo Corporation $MASI Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its position in shares of Masimo Corporation (NASDAQ:MASI) by 39.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 8,919 shares of the medical equipment provider’s stock after selling 5,847 shares during the quarter. SG Americas Securities LLC’s holdings in Masimo were worth $1,316,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. MAI Capital Management grew its stake in Masimo by 176.7% during the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 129 shares during the period. Hilltop National Bank acquired a new position in shares of Masimo during the 2nd quarter valued at $37,000. Allworth Financial LP lifted its holdings in shares of Masimo by 72.8% during the 2nd quarter. Allworth Financial LP now owns 387 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 163 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Masimo during the 2nd quarter worth $86,000. Finally, Farther Finance Advisors LLC increased its holdings in Masimo by 423.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,074 shares of the medical equipment provider’s stock valued at $158,000 after purchasing an additional 869 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

Masimo stock opened at $142.05 on Friday. Masimo Corporation has a 52 week low of $125.94 and a 52 week high of $194.88. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69. The stock has a market cap of $7.63 billion, a P/E ratio of -13.48, a price-to-earnings-growth ratio of 1.43 and a beta of 1.26. The stock has a 50 day moving average of $139.25 and a 200-day moving average of $146.26.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 4th. The medical equipment provider reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The firm had revenue of $371.20 million for the quarter, compared to analysts’ expectations of $366.89 million. During the same period in the prior year, the company posted $0.86 earnings per share. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. On average, analysts expect that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. BTIG Research boosted their price target on Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Bank of America assumed coverage on shares of Masimo in a research report on Monday, November 17th. They issued a “neutral” rating and a $162.00 price objective for the company. Wells Fargo & Company reissued an “overweight” rating and set a $190.00 target price on shares of Masimo in a research report on Friday, December 5th. Finally, Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo presently has an average rating of “Hold” and an average price target of $189.40.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.